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It is under debate whether healthcare costs related to death and in life years gained (LysG) due to life saving interventions should be
included in economic evaluations. We estimated the impact of including these costs on cost-effectiveness of cancer screening. We
obtained health insurance, home care, nursing homes, and mortality data for 2.1 million inhabitants in the Netherlands in 1998–1999.
Costs related to death were approximated by the healthcare costs in the last year of life (LastYL), by cause and age of death. Costs in
LYsG were estimated by calculating the healthcare costs in any life year. We calculated the change in cost-effectiveness ratios (CERs)
if unrelated healthcare costs in the LastYL or in LYsG would be included. Costs in the LastYL were on average 33% higher for persons
dying from cancer than from any cause. Including costs in LysG increased the CER by h4040 in women, and by h4100 in men. Of
these, h660 in women, and h890 in men, were costs in the LastYL. Including unrelated healthcare costs in the LastYL or in LYsG will
change the comparative cost-effectiveness of healthcare programmes. The CERs of cancer screening programmes will clearly
increase, with approximately h4000. However, because of the favourable CER’s, including unrelated healthcare costs will in general
have limited policy implications.
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Cancer screening induces both costs and savings (Stone et al,
2000). Savings occur due to avoided treatment of advanced disease
and palliative care, whereas the costs increase because of screening
activities and because more cases of (preinvasive) neoplasia will be
found than in the situation without screening.
Cost-effectiveness analysis, the standard analytic tool support-
ing medical decision making, involves estimating the costs and
effects of an intervention compared with an alternative, for
example, the care that would be given if the intervention was not
used at all, or with a different intensity of the intervention under
investigation, such as less frequent screening (Russell et al, 1996).
One of the most persistent unresolved issues in the use of
cost-effectiveness analysis is the application of the healthcare
costs related to postponed death, or more in general, of unrelated
healthcare costs in life years gained (LysG; Garber et al, 1996). It
is increasingly argued that economic evaluations should include
these costs to be consistent (Nyman, 2004), as LysG due to
spending unrelated healthcare costs are generally included.
However, the most common practice is to include medical cost
for illnesses related to the intervention, and to ignore increases in
medical expenditures due to other illnesses that arise during the
LysG. A particular kind of unrelated healthcare costs in LysG are
medical costs related to death from another cause (Meltzer, 1997).
As increasing life expectancy due to preventive interventions
simply postpones the costs related to death, it is believed that not
considering these costs would overestimate the savings in
healthcare costs (Gandjour and Lauterbach, 2005). Future un-
related healthcare costs might be large enough to raise the CER to
such a degree that the ranking of alternative interventions can be
changed, which constitutes important information to policy-
makers. The impact is greatest when the intervention primarily
extends life, such as is the case with cancer screening (Garber and
Phelps, 1997).
We considered both: (1) including the healthcare costs related
to postponed death, regardless of its cause and (2) more in general
of including the unrelated healthcare costs in LysG. As a proxy
of costs related to death, we studied the healthcare costs in the
last year of life (LastYL), discerning between deaths caused by a
specific cancer (focusing on cancers for which screening is
recommended or at least under discussion) from deaths due to
any cause. We also investigated the healthcare costs in the LysG
and how they depend on age. Finally, to understand the potential
impact, we calculated the increase these costs would make on the
estimated CER.
MATERIALS AND METHODS
We obtained health insurance data for 1998 and 1999 for a sample
of 2.1 million inhabitants, representing 13.4% of the whole Dutch
population in 1999. The study group is representative for the
Dutch population regarding age, gender, and cause of death
(Polder et al, 2006). Of the study population, 66.5% was insured by Received 3 March 2009; revised 6 March 2009; accepted 12 March 2009
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ssocial health insurance and 33.5% by private health insurance,
which was in line with the corresponding distribution in the
general population in 1999 (63.5 vs 36.5% insured by social and
private health insurance, respectively) (Statistics Netherlands,
2008). Both insurance schemes covered a similar package of
healthcare services. The health services we included were the
expenses for physicians, primary care, hospitals, drugs, and related
services. We also included expenditures on nursing homes and
home care. A detailed description of the health services included,
the study group and the cost calculation, and projection is
presented elsewhere (Polder et al, 2006).
The data on nursing homes and home care were linked with
health insurance data at individual level, using birth date, sex, and
zip code. The registration of home care was complete. The nursing
homes registry covered 65% of the users of nursing home care. As
the coverage appeared to be non-selective, we adjusted the average
nursing home costs in our study population, using a correction
factor depending on coverage per geographical area (on average:
100/65).
Subsequently, to obtain date and cause of death, the data of the
health insurance companies was linked with mortality data from
Statistics Netherlands, using birth date, sex, and zip code. In the
final analysis, we distinguished between costs of survivors
(n¼2093748) and decedents (n¼14839), the latter stratified by
cause of death. All individuals who entered or dropped out the
study population in 1998 or 1999, for example due to a change in
their insurance scheme, or individuals who died in 1998, were
excluded from the study. Also, individuals who died in 2000 were
excluded, because part of their health expenditures in 1999 could
include costs related to death.
Healthcare cost in the LastYL
The costs before dying were approximated by the healthcare costs
in the LastYL. For decedents in 1999, we calculated health
expenditures in the 365 days before death. For privately insured
decedents, we had information on the date of death and total
healthcare expenditure for the individual years 1998 and 1999, as
well as the exact health expenditures during the LastYL. For
individuals with a social health insurance scheme, we had
information on the date of death and the total healthcare
expenditure for the separate years 1998 and 1999, but not the
exact health expenditures during the LastYL. We, therefore,
interpolated the cost in the LastYL for individuals with social
health insurance. As health expenditure is increasing within the
LastYL, we used a non-linear interpolation method. We divided
the privately insured population into 12 groups according to the
month of death in 1999, and for each group calculated the fraction
of the 1998 expenditure that belonged to the LastYL. As the month
of death of the decedents with social insurance schemes was
known, we could use these fractions to estimate the share of their
individual 1998 expenditure that belonged to the LastYL. We
calculated the costs in the LastYL under the assumption that the
distribution of the costs over the LastYL (not the level of those
costs) is comparable for both groups of insurance.
We calculated the 95% confidence intervals for healthcare costs
in the LastYL on the basis of a lognormal distribution. This was
not possible for the costs of nursing homes, because for this cost
category, only average figures on group level were available (by
age, gender, and cause of death). The costs before dying were
stratified by age, gender, and cause of death. We stratified the
causes of death into five types of cancer that are potentially
preventable due to screening (lung, colon, prostate, breast, and
cervical cancer) all cancer and causes (Figure 1). On account of the
small number of decedents in the younger age groups, we used an
asymmetric age structure: 0–44, 45–54, and 55–64 years, and
from then on 5-year categories ending with the category 95 years
and older (Figure 2).
Healthcare costs in LysG
We calculated the average healthcare costs in the LysG, by gender
and age category at which death is prevented. To do so, we first
calculated the average annual healthcare costs by age and gender,
using costs in ‘survivors’ (Figure 3). In this way, these annual costs
were cleared from the costs in the LastYL. Second, we summated
these annual healthcare costs for each specific expected life year
gained (LyG). The expected number of LysG for individuals whose
death is prevented (postponed) by screening were estimated by age
at which death is prevented and gender, using life tables for the
Dutch population (Statistics Netherlands, 2007). Third, we added
up the costs in the expected LysG in survivors and the costs in the
LastYL.
Increase in costs per LyG
We calculated the increase in costs per LyG when taking into
account both the unrelated healthcare costs of dying (Table 1) and
the unrelated healthcare costs during LysG (Table 2), by gender
and age at which death is prevented (postponed), undiscounted
and discounted (costs and LysG by 3% towards the age of 50 years,
assuming screening starts at that age). To do so, we divided the
calculated healthcare costs in the substituting LastYL and the
healthcare costs in LysG, respectively, by the average number
of LysG.
As an example, we calculated the impact of the above estimated
extra costs per LyG on the CER of breast cancer screening,
assuming that the mean age at breast cancer death (68 years
(Netherlands Cancer Registry (NCR), 2005)) is the average age at
which death is prevented by breast cancer screening in our
population. Here, we used evidence from literature on cost-
effectiveness of breast cancer screening without accounting for the
evaluated unrelated healthcare costs (Groenewoud et al, 2004).
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Figure 1 Mean (95% confidence intervals) healthcare costs in the last
year of life, by cause of death (excluding nursing home care).
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Figure 2 Mean healthcare costs in the last year of life by age group, all
causes of death.
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sIncluded in this cost-effectiveness analysis were costs of screening,
and the costs of diagnostics, primary treatment, follow-up, and
palliative care of breast cancer. The effect of screening was
estimated by the difference in number of life years lost due to
breast cancer with and without screening. Costs and effects were
adjusted with a 3% annual discount rate.
All costs and CERs were indexed according to the price level of
2008 using the consumer price index.
RESULTS
The healthcare costs in the LastYL were significantly higher for
individuals who died from cancer than for those who died from
any cause (h21700 vs h16300; Figure 1). The costs in individuals
who died of cervical cancer were the highest (h29700), partly
explained by the fact that cervical cancer patients die at a relative
younger age. Nevertheless, the difference with dying from other
cancers was not significant due to the small number of cervical
cancer death cases. Considering all causes of death, healthcare
costs in the LastYL decreased with age (h26800 in age-group 0–44
to h7500 in age-group 95þ; Figure 2). The average yearly
healthcare costs increased with age (h800 in age group 0–44 years
to h4600 in age-group 95þ years; Figure 3).
Table 1 shows the increase in costs per LyG if unrelated
healthcare costs in the postponed LastYL are taken into account.
After discounting, costs per LyG increase for men on average by
h680, and for women by h480. This increase in costs per LyG
increases with age at which death is prevented, despite the fact that
the costs in the LastYL decrease with age (Figure 2). The reason is
that the number of LysG, the denominator in the equation,
decrease with age.
Table 2 shows the increase in costs per LyG when unrelated
healthcare costs in LysG is taken into account. After discounting,
costs per LyG increase for men on average by h4100 and for
women by h4000. This increase becomes larger with age at which
death is prevented, because the yearly healthcare costs increase
with age (Figure 3).
The effect of discounting on the increase in costs per LyG is
limited, because both costs, as well as LysG, are discounted at the
same rate (3% per year).
The overall impact depends on the CER before the adjustment.
For breast cancer screening in the Netherlands, for example, this
ratio was estimated at approximately h2700 per LyG (UKd1515 in
2002; Groenewoud et al, 2004). If healthcare costs unrelated to the
prevented breast cancer in the LysG are taken into account, the
CER would increase to approximately h7300 per LyG, which means
an increase of 171%. If only the unrelated healthcare costs in the
postponed LastYL are taken into account, the CER would increase
to approximately h3200 per LyG, which is an increase of 20%. The
effect would have been smaller if screening prevented death at
younger ages, whereas a larger increase would occur if age at
prevented death would have been higher.
DISCUSSION
We showed that the healthcare costs in the LastYL are higher than
the mean yearly healthcare costs and that the former costs decrease
with age, whereas the latter increase with age. The costs in the
LastYL are higher for individuals who die from cancer than for
those who die from any cause. If we take medical costs in the
postponed LastYL into account, costs per LyG increase between
h360 and h890, depending on age and gender. These higher costs
occur because in traditional cost-effectiveness calculations the
savings of prevented cure and care are overestimated, as the costs
of dying are only postponed rather than avoided. If, instead, we
take unrelated healthcare costs in all LysG into account, the costs
per LysG increase between h3100 and h5200. This effect increases
with age at which death is prevented by screening.
The specification of which costs to include in the analysis
depends on the perspective of the economic evaluation (Russell
et al, 1996). Unrelated healthcare costs in LysG need to be included
from the perspective of the health services. From the societal
perspective, however, all costs and effects resulted from the
intervention need to be considered. Therefore, if medical costs in
LysG are included in the evaluation, non-medical costs in LysG
and productivity gains should also be included. However, because
of practical concerns, for example, lack of data, and unresolved
theoretical issues surrounding the inclusion of costs in added life
years, researchers often do not include these costs. Thereby,
researchers can choose to neglect unrelated healthcare costs in
LysG, as the guidelines for economic evaluations are not explicit
on the inclusion of these costs. As costs related to death can be
regarded as a correction of the savings, because they are not
prevented, but only postponed by prevention (Gandjour and
Lauterbach, 2005), they can be included from the perspective of the
health services as well as from the societal perspective.
Table 1 Increase in costs per life year gained when taking into account
healthcare costs in the postponed last year of life, by sex and age at which
death is prevented (discounted at 0 and 3%)
Age at prevented
0% discounting 3% discounting
death (years) Men Women Men Women
50–54 h 600 h 460 h 500 h 360
55–59 h 710 h 540 h 630 h 450
60–64 h 880 h 650 h 700 h 500
65–69 h 1,100 h 790 h 800 h 550
70–74 h 1,360 h 980 h 890 h 610
Mean h 890 h 660 h 680 h 480
Table 2 Increase in costs per life year gained when taking into account
unrelated healthcare costs in life years gained, by sex and age at which
death is prevented (discounted at 0 and 3%)
Age at prevented
0% discounting 3% discounting
death (years) Men Women Men Women
50–54 h 3280 h 3370 h 3120 h 3190
55–59 h 3650 h 3710 h 4150 h 3880
60–64 h 4140 h 4140 h 4040 h 4400
65–69 h 4750 h 4640 h 4640 h 4580
70–74 h 5370 h 5150 h 5170 h 5070
Mean h 4110 h 4100 h 4100 h 4040
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Figure 3 Mean healthcare costs per life year, by age group.
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LastYL was limited, because prevention of cancer death on average
replaces a rather expensive LastYL of relatively young individuals
with a less costly LastYL at a higher age. The fact that the LastYL of
individuals who die of cancer is relatively expensive was also found
by studies from the United States (Riley et al, 1987; Riley and
Lubitz, 1989; Koroukian et al, 2006) and from Australia
(Kardamanidis et al, 2007). That unrelated healthcare costs in
the LastYL are higher for cancer patients than for other decedents
can be explained by intensive and more expensive treatment.
Furthermore, the group of other decedents includes a substantial
fraction of ‘sudden death’, among others by myocardial infarc-
tions, strokes, and accidents (Wong et al, 2006). Given the higher
costs of cancer deaths and because healthcare costs related to
death decrease with age, simply shifting the costs related to a
prevented cancer death to the future will underestimate the total
costs of the intervention. Discounting of future costs reduces the
impact on the CER of including the postponed costs even further.
On the other hand, if age-related disutility during added life years
is considered, the impact on the CER (costs per quality-adjusted
LyG) would increase, as added life years are lived at older ages, and
the quality of these life years is relatively less.
As the CER of cancer screening increases when unrelated
healthcare costs in the postponed LastYL or in all LysG are taken
into account, including these costs in the cost-effectiveness
analyses may have impact on the policy decisions about a
particular screening programme, also because the optimal (from
a cost-effective point of view) screen policy may change. On the
other hand, if these costs are included, for example, for the current
breast cancer screening programme in the Netherlands, the costs
per LyG still are acceptable according the Dutch threshold value of
about h20000 per quality-adjusted LyG. The CER (without
including costs in the LastYL or in LysG) of other cancer screening
programmes in the Netherlands, such as cervical cancer screening
(h9500 per LyG (van Ballegooijen et al, 2006)), and faecal occult
blood test-based colorectal cancer screening (h15000 per LyG
(Pignone et al, 2002)), also remain under the acceptability
threshold. The increase in CER for colorectal cancer screening
will be higher than the increase in CER for cervical cancer
screening, because the average age at which death is prevented is
higher for colorectal cancer screening than for cervical cancer
screening (Tables 1 and 2).
By including unrelated healthcare costs in the LastYL as well as
in LysG, the CER of prevention of lethal illnesses can become less
favourable compared with the prevention of non-lethal illnesses.
Vaccination during childhood against, for example, mumps and
rubella, prevents a lot of severe disabilities, but in developed
countries, individuals rarely die of those diseases in the absence of
vaccination. As a consequence, there are no healthcare costs
related to postponed death or in LysG in this situation. Therefore,
the CER of prevention of these non-lethal illnesses will not change.
Bonneux et al (1998) showed that elimination of fatal diseases,
such as cancer, significantly increases the life-time expected
healthcare costs. They found that the elimination of cancer will
increase the healthcare costs with h2300 (d912 in 1988) and h3000
(d1190 in 1988) per LyG for men and women, respectively. The
difference between these results and our estimated increase in
costs per LyG, when taking into account healthcare costs in LysG,
is explained by the fact that healthcare costs have increased in the
last 20 years (World Health Organisation (WHO), 16/02/2009).
In the meantime, when cost-effectiveness analyses are used for
policy decisions, it is important that any type of costs are either
consistently excluded or consistently included (van Baal et al,
2007).
Strengths and weaknesses
The strength of our study is that we linked healthcare costs to the
official mortality register on the individual level, and were,
therefore, able to analyse cost differences per cause of death. Also,
we included all medical care costs, whereas most other studies
focus on hospital care only. Thereby, due to the fact that the
government heavily regulates the Dutch healthcare system, the
claims on the health insurance are very comparable to the actual
healthcare costs that makes the estimation of the medical costs
reliable.
A potential weakness is that we used average annual healthcare
expenditures as an estimate of the yearly healthcare costs of
individuals whose cancer death is prevented by cancer screening,
whereas individuals whose cancer death is prevented may tend to
have a more active healthcare-seeking pattern. Also, there is some
evidence that individuals diagnosed with cancer have an increased
risk of other diseases due to the fact that the risk factor that played
a role in the development of cancer can cause other diseases as well
(Eakin et al, 2007; Soerjomataram, 2007). The symptoms or
illnesses that generate the possible higher expenses in individuals
whose cancer death is prevented are not directly related to the
illness for which death was prevented, and are therefore
considered as unrelated healthcare costs. As a consequence, the
assumption that these individuals have average annual unrelated
healthcare expenditures, may have led to a slight underestimation
of the increase in costs per LyG.
Finally, as we mentioned before, it is argued that for an
evaluation from a societal perspective non-medical costs and
benefits in LysG, that is, productivity gains, paid pensions, and
non-health-related quality of life need to be included in economic
evaluations (Liljas et al, 2008). We did not take into account these
issues, as they go beyond the scope of this study, but should be
studied in the continuing debate on costs and benefits of
prevention.
In conclusion, taking the unrelated healthcare costs in the
postponed LastYL or during all LysG into account in cost-
effectiveness analyses will change the relative cost-effectiveness of
healthcare programmes and may influence priority settings. The
CERs of cancer screening programmes will clearly increase, with
approximately h4000. However, because of the favourable CERs,
including unrelated healthcare costs in LysG will, in general, have
limited policy implications.
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